Article
Oncology
Jung Sun Kim, Koung Jin Suh, Dae-Won Lee, Go-Un Woo, Miso Kim, Se Hyun Kim, Han Suk Ryu, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, So Yeon Park, In Ae Park, Jee Hyun Kim, Seock-Ah Im
Summary: This study aimed to assess the real-world efficacy of nab-paclitaxel in metastatic breast cancer patients. The results showed that nab-paclitaxel is a reasonable treatment option for heavily pre-treated and/or taxane-exposed patients with metastatic breast cancer.
CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Priyanka Sharma, Vandana G. Abramson, Anne O'Dea, Lauren Nye, Ingrid Mayer, Harsh B. Pathak, Marc Hoffmann, Shane R. Stecklein, Manana Elia, Sharon Lewis, Jecinta Scott, Jilliann A. De Jong, Yen Y. Wang, Rachel Yoder, Kelsey Schwensen, Karissa Finke, Jaimie Heldstab, Stephanie LaFaver, Stephen K. Williamson, Milind A. Phadnis, Gregory A. Reed, Bruce F. Kimler, Qamar J. Khan, Andrew K. Godwin
Summary: The combination of alpelisib and nab-paclitaxel showed good tolerability and promising efficacy in patients with HER2-negative metastatic breast cancer, especially in those with PIK3CA-mutated tumor/ctDNA. The impact of metabolic status on treatment response warrants further investigation.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Yizhao Xie, Chengcheng Gong, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Ting Li, Yannan Zhao, Yi Li, Shihui Hu, Biyun Wang, Xichun Hu
Summary: This phase II trial demonstrated satisfactory efficacy and safety of nab-paclitaxel in metastatic breast cancer patients with visceral metastases, with better treatment outcome for patients in first line therapy. Further alternatives may be required for patients with premenopausal status or brain metastasis. The study also showed the efficacy and safety of 125 mg/m2 nab-paclitaxel among Asian patients.
Article
Oncology
Jung Won Chun, Sang Hyub Lee, Joo Seong Kim, Namyoung Park, Gunn Huh, In Rae Cho, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim
Summary: FFX achieved longer overall survival and progression free survival in mPC patients compared to GnP, but there was no significant difference in sequential treatment. However, GnP was associated with more frequent toxicities, leading to more interruptions in chemotherapy and poorer survival outcomes.
Review
Oncology
Haili Lu, Siluo Zha, Wei Zhang, Qiang Wang, Daozhen Jiang, Xinyun Xu, Xiangmin Zheng, Ming Qiu, Chengxiang Shan
Summary: Nab-paclitaxel mono-chemotherapy shows considerable benefits in the treatment of MBC with manageable harm. Further studies are needed to evaluate the roles of dosage, schedule, and other factors in nab-paclitaxel chemotherapy.
Article
Biotechnology & Applied Microbiology
Weiwei Zhang, Yinggang Xu, Xiaoqing Shi, Xiaofeng Huang, Rui Chen, Haiping Xu, Wenjie Shi, Xinyu Wan, Ye Wang, Jinzhi He, Cuiying Li, Jue Wang, Xiaoming Zha
Summary: This study retrospectively compared the efficacy and safety of two potential neoadjuvant systemic treatment drugs, liposomal paclitaxel (Lps-P) and nanoparticle albumin-bound paclitaxel (Nab-P), in breast cancer. The results showed that more participants who received Nab-P had no signs of cancer in their breast and axillary lymph nodes than participants who received Lps-P. Although Nab-P can cause a higher incidence and severity of peripheral sensory neuropathy (PSN), most symptoms are temporary and reversible. In conclusion, Nab-P might be superior to Lps-P for neoadjuvant systemic treatment of breast cancer.
Article
Biotechnology & Applied Microbiology
Yan Li, Xiang Chen, Qiannan Zhu, Rui Chen, Lu Xu, Shuo Li, Xiaoqing Shi, Haiping Xu, Yinggang Xu, Weiwei Zhang, Xiaofeng Huang, Xiaoming Zha, Jue Wang
Summary: The study compared the efficacy and safety of 2-weekly nanoparticle albumin-bound paclitaxel (nP) and 3-weekly docetaxel regimens as neoadjuvant systemic therapy for breast cancer. The nP group achieved higher pathological complete response rates, especially in patients with triple-negative tumor cells and high Ki67 levels. However, grades 3-4 peripheral sensory neuropathies were more frequent in the nP group.
Article
Oncology
Yimeng Chen, Baoshi Bao, Yao Lv, Decong Sun, Li Zhang, Jiandong Wang, Weihong Zhao
Summary: This study retrospectively evaluated the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-PTX) and docetaxel (DOC) as neoadjuvant therapy in breast cancer patients. The results showed a higher pathologic complete response rate in the nPBC group compared to the DBC group, indicating potential benefits of nab-PTX-based chemotherapy in early breast cancer treatment.
INVESTIGATIONAL NEW DRUGS
(2021)
Review
Oncology
Miao Liu, Siyao Liu, Liu Yang, Shu Wang
Summary: This study compared the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and solvent-based taxanes (sb-taxanes) as neoadjuvant therapy in breast cancer treatment, with nab-paclitaxel showing improved pathological complete response rate and event-free survival compared to sb-taxanes.
Review
Biotechnology & Applied Microbiology
Suhana Ahmad, Lidawani Lambuk, Naveed Ahmed, Ali Mussa, Vincent Tee, Ros Akmal Mohd Idris, Nur Fazimah Sahran, Yean Yean Chan, Rosline Hassan, Yeong Yeh Lee, Rohimah Mohamud
Summary: Nab-paclitaxel demonstrates good efficacy and safety in the treatment of metastatic gastric cancer, providing better disease response and longer survival.
Article
Oncology
Yaxin Liu, Guohong Song, Lijun Di, Hanfang Jiang, Ran Ran, Ruyan Zhang, Yan Zhang, Huiping Li
Summary: This study compared the efficacy and safety of a 3-week versus 4-week schedule of nab-paclitaxel in patients with metastatic breast cancer, and found that the 3-week schedule had a longer progression-free survival and a lower rate of toxicity-related treatment discontinuation and dose delays compared to the 4-week schedule.
Article
Oncology
Gerald W. Prager, Leopold Oehler, Armin Gerger, Brigitte Mlineritsch, Johannes Andel, Andreas Petzer, Klaus Wilthoner, Thamer Sliwa, Petra Pichler, Thomas Winder, Sonja Heibl, Birgit Gruenberger, Friedrich Laengle, Eva Hubmann, Markus Korger, Martin Pecherstorfer, Angela Djanani, Hans-Joerg Neumann, Kathrin Philipp-Abbrederis, Ewald Woll, Robert Trondl, Catharina Arnold-Schrauf, Wolfgang Eisterer
Summary: This study confirms the feasibility and tolerability of nab-P/G treatment in younger and elderly patients with mPC, with similar efficacy. Older patients were more likely to experience fatigue and reduced appetite, but overall response rates, progression-free survival, and overall survival were comparable between younger and elderly patients.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Zhi-Dong Lv, Hong-Ming Song, Zhao-He Niu, Gang Nie, Shuai Zheng, Ying-Ying Xu, Wei Gong, Hai-Bo Wang
Summary: This retrospective study compared the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with docetaxel as neoadjuvant regimens for HER2-negative breast cancer. The study found that nab-paclitaxel achieved a higher pathological complete response rate in some patients compared to docetaxel, but there was no significant difference in disease-free survival between the two groups. There were also differences in drug-related adverse events between the two groups.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
L. A. Emens, S. Adams, C. H. Barrios, V Dieras, H. Iwata, S. Loi, H. S. Rugo, A. Schneeweiss, E. P. Winer, S. Patel, V Henschel, A. Swat, M. Kaul, L. Molinero, S. Patel, S. Y. Chui, P. Schmid
Summary: The study showed that although A + nP for first-line treatment of triple-negative breast cancer did not significantly improve overall survival in the overall population, clinically meaningful benefits were observed in patients with PD-L1 expression on tumor infiltrating immune cells. The combination therapy remained safe and tolerable with longer follow-up.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
O. Gluz, S. Kuemmel, U. Nitz, M. Braun, K. Luedtke-Heckenkamp, R. von Schumann, M. Darsow, H. Forstbauer, J. Potenberg, C. Uleer, E. M. Grischke, B. Aktas, C. Schumacher, C. zu Eulenburg, R. Kates, K. Jozwiak, M. Graeser, R. Wuerstlein, R. Baehner, M. Christgen, H. H. Kreipe, N. Harbeck
Summary: In high-risk HR+/HER2- early breast cancer, nanoparticle albumin-bound (nab)-paclitaxel showed promising efficacy versus solvent-based (sb)-paclitaxel in neoadjuvant trials. However, optimal patient and therapy selection remains a topic of ongoing research.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Mario Caccese, Anna Maria Saieva, Valentina Guarneri, Sara Lonardi, Massimo Cacco, Vanna Chiarion Sileni, Michele Gottardi, Eleonora Mioranza, Francesca Bergamo, Antonella Brunello, Vittorina Zagonel, Patrizia Benini
Summary: Routine testing for SARS-CoV-2 in asymptomatic and fully vaccinated cancer patients during treatment did not appear to be cost-effective. Out of 2439 cancer patients screened, only 2.17% tested positive, and 92.5% had their cancer treatment discontinued as a precaution.
Article
Oncology
Maria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, Antonio Frassoldati, Roberto Vicini, Sara Balduzzi, Roberto Damico, Pierfranco Conte, Valentina Guarneri
Summary: The optimal adjuvant endocrine therapy for HR-positive/HER2-positive breast cancer patients is unknown. In this analysis of the ShortHER trial, 784 patients with HR-positive/HER2-positive BC were included, and it was found that AI treatment was associated with significantly better disease-free survival (DFS) compared to TAM or TAM-AI treatment. Among premenopausal patients aged <= 45 years, the use of GnRHa was also associated with longer DFS.
Article
Obstetrics & Gynecology
Caterina Barbieri, Ottavia Amato, Anna Chiara Cattelan, Loris Marin, Alessandra Andrisani, Carlo Saccardi, Tommaso Giarratano, Giovanni Faggioni, Elisabetta Di Liso, Carlo Alberto Giorgi, Eleonora Mioranza, Cristina Falci, Grazia Maria Vernaci, Roberto Tozzi, Valentina Guarneri, Maria Vittoria Dieci
Summary: One main issue in young breast cancer patients is the impact of oncological treatments on fertility. The COVID-19 pandemic has affected the integration of fertility procedures into clinical practice. This study aims to describe the time-related evolution in addressing oncofertility issues.
CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY
(2023)
Article
Oncology
Carmine Valenza, Dario Trapani, Sara Gandini, Caterina Sposetti, Luca Boscolo Bielo, Antonio Marra, Tommaso Giarratano, Diletta Favero, Laura Cortesi, Luca Moscetti, Mirco Pistelli, Rossana Berardi, Alberto Zambelli, Matteo Lambertini, Lucia Del Mastro, Valentina Guarneri, Claudio Vernieri, Giuseppe Curigliano
Summary: Patients with germinal BRCA pathogenic variant and advanced breast cancer may have enhanced sensitivity to platinum-based chemotherapy and PARP inhibitors. However, the sensitivity and resistance to these treatments may partially overlap. The impact of prior exposure to PARP inhibitors/platinum-based chemotherapy on tumor response to subsequent treatment remains unclear.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Luca Malorni, Giampaolo Bianchini, Roberta Caputo, Alberto Zambelli, Fabio Puglisi, Giulia Bianchi, Lucia Del Mastro, Ida Paris, Filippo Montemurro, Giacomo Allegrini, Marco Colleoni, Stefano Tamberi, Claudio Zamagni, Marina E. Cazzaniga, Michele Orditura, Valentina Guarneri, Daniela Castelletti, Matteo Benelli, Mariacristina Di Marino, Grazia Arpino, Michelino De Laurentiis
Summary: In this study, it was found that serum TK1 activity (sTKa) can serve as a novel prognostic and pharmacodynamic biomarker in patients with HR+/HER2- ABC treated with ribociclib plus letrozole as first-line therapy.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Gaia Griguolo, Vittoria Aldegheri, Michele Bottosso, Alice Pittaro, Francesca Caumo, Maria Cristina Guarascio, Stephane Pouderoux, Fabio Busato, Federica Miglietta, William Jacot, Maria Vittoria Dieci, Amelie Darlix, Valentina Guarneri
Summary: This study validates the prognostic impact of treatment response assessed using the RANO criteria in patients with leptomeningeal metastases. The study found that the radiological response according to the 2019 RANO criteria was significantly associated with overall survival in patients with breast cancer related leptomeningeal metastases.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Pathology
Federica Miglietta, Valentina Carraro, Ottavia Amato, Gaia Griguolo, Michele Bottosso, Giada Munari, Giovanni Zarrilli, Marcello Lo Mele, Caterina Barbieri, Angelo Paolo Dei Tos, Valentina Guarneri, Maria Vittoria Dieci, Matteo Fassan
Summary: This study aims to track the dynamics of the PI3K/PTEN/mTOR pathway in HR+/HER2- breast cancer patients receiving neoadjuvant chemotherapy. The results show that this pathway is highly dynamic and may play a crucial role in shaping the molecular landscape of breast cancer with residual disease after chemotherapy.
JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Oncology
Ippazio Cosimo Antonazzo, Paolo Angelo Cortesi, Gerardo Miceli Sopo, Giampiero Mazzaglia, Pierfranco Conte, Lorenzo Giovanni Mantovani
Summary: This study aimed to assess the cost and cost-effectiveness of tucatinib when used in combination with trastuzumab and capecitabine compared to TDM-1 for HER2(+) breast cancer. The findings suggest that TCX is cost-effective at a willingness to pay of 60,000 EUR, while TDM-1 is more cost-effective at a willingness to pay of 20,000 EUR. The results can be used to ensure the affordability of tucatinib in Italy and provide a pricing threshold for other countries.
Article
Oncology
L. Cortesi, M. Venturelli, G. Cortesi, F. Caggia, A. Toss, E. Barbieri, U. De Giorgi, V. Guarneri, A. Musolino, E. De Matteis, A. Zambelli, G. Bisagni, M. Dominici
Summary: In this clinical trial, the efficacy and safety of pembrolizumab plus carboplatin in treating first-line visceral disease BRCA-related luminal breast cancer were investigated. The primary aim of achieving an overall response rate >70% was not met, but further investigation is needed.
Article
Oncology
Nicola Normanno, Antonella De Luca, Riziero Esposito Abate, Alessandro Morabito, Michele Milella, Fabrizio Tabbo, Giuseppe Curigliano, Cristina Masini, Paolo Marchetti, Giancarlo Pruneri, Valentina Guarneri, Giovanni L. Frassineti, Gianpiero Fasola, Vincenzo Adamo, Bruno Daniele, Rossana Berardi, Florinda Feroce, Evaristo Maiello, Carmine Pinto
Summary: The Italian Register of Actionable Mutations is a multicentric observational study that collects next-generation sequencing data of patients with advanced solid tumors. The study identifies the rate of actionable mutations and highlights the utility of comprehensive genomic profiling in selected cancer patients.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
PierFranco Conte, Giancarlo Bisagni, Federico Piacentini, Samanta Sarti, Santino Minichillo, Elisa Anselmi, Michele Aieta, Vittorio Gebbia, Alessio Schirone, Antonino Musolino, Ornella Garrone, Alessandra Beano, Anita Rimanti, Francesco Giotta, Anna Turletti, Federica Miglietta, Maria Vittoria Dieci, Roberto Vicini, Sara Balduzzi, Robert D'Amico, Valentina Guarneri
Summary: This article presents the final analysis of a clinical trial comparing different durations of adjuvant chemotherapy with trastuzumab in HER2+ early breast cancer patients. The results show that the differences in efficacy between one year and nine weeks of trastuzumab are negligible for patients at low or intermediate risk, while patients with N4+ status benefit significantly from one year of treatment.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Pierre D. Squifflet, Everardo Saad, Sibylle T. Loibl, Marion van Mackelenbergh, Michael Untch, Priya Rastogi, Luca Gianni, Andreas Schneeweiss, Pierfranco Conte, Martine Piccart, Herve Bonnefoi, Christian Jackisch, Valentina Nekljudova, Gong Tang, Pinuccia Valagussa, Colin Neate, Richard Gelber, Coralie Poncet, Dominik Heinzmann, Carsten E. Denkert, Charles Geyer Jr, Javier Cortes, Valentina Guarneri, Evandro de Azambuja, David Cameron, Gustavo Ismael, Norman Wolmark, Patricia Cortazar, Marc Buyse, CTNeoBC Project
Summary: This study analyzed data from 15 randomized trials and found that although pCR is strongly associated with event-free survival and overall survival at the patient level, these associations are weak at the trial level.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Marion van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc Buyse, Charles E. Geyer, Luca Gianni, Andreas Schneeweiss, Pierfranco Conte, Martine Piccart, Herve Bonnefoi, Christian Jackisch, Valentina Nekljudova, Gong Tang, Pinuccia Valagussa, Colin Neate, Richard Gelber, Coralie Poncet, Pierre Squifflet, Everardo D. Saad, Dominik Heinzmann, Carsten Denkert, Priya Rastogi, Javier Cortes, Valentina Guarneri, Evandro de Azambuja, David Cameron, Gustavo Ismael, Norman Wolmark, Patricia Cortazar
Summary: Achieving pCR is important for the prognosis of EFS and OS in patients with early breast cancer. This study investigates prognostic factors for EFS and OS in patients with and without pCR after neoadjuvant therapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Maria Vittoria Dieci, Pierfranco Conte, Giancarlo Bisagni, Stefania Bartolini, Antonio Frassoldati, Daniele Generali, Federico Piacentini, Gaia Griguolo, Enrico Tagliafico, Fara Braso Maristany, Nuria Chic, Laia Pare, Federica Miglietta, Roberto Vicini, Roberto D'Amico, Sara Balduzzi, Aleix Prat, Valentina Guarneri
Summary: The integration of intrinsic molecular subtypes with stage or HER2DX risk score can predict site-specific metastatic risk in HER2-positive breast cancer, potentially impacting personalized surveillance and preventing site-specific recurrence in clinical trials.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)